Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Cancel anytime.
Andrea Corona MapLight reports mixed results in Schizophrenia trial In their Phase 2 ZEPHR trial, MapLights novel oral drug for schizophrenia, the Ml/M4 muscarinic agonist ML-007C-MA, successfully hit its primary endpoint but only for the twice-daily version, not the once-daily dose
Probably because the studies, although promising, were not considered to have any major therapeutic benefit
It provides benzodiazepine-like anxiolytic effects without sedation, cognitive impairment, or dependence risk
Online sources sometimes group this treatment with skin lightening injections, however that description oversimplifies its biological role
Fibroblasts secrete various biological substances, such as Vascular Endothelial Growth Factor (VEGF)
